Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

  • Guo S
  • Chen D
  • Huang X
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRas mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizing a cetuximab mouse clinical trial (MCT) dataset on a cohort of 25 randomly selected EGFR + CRC patient-derived xenografts (PDXs). While we found that the expression of EGFR and its ligands are not predictive of the cetuximab response, we tested a published Ras pathway signature, a 147-gene expression signature proposed to describe Ras pathway activity, against this MCT dataset. Interestingly, our study showed that the observed cetuximab activity has a strong correlation with the Ras pathway signature score, which was also demonstrated to have a certain degree of correlation with a historic clinical dataset. altogether, the independent validations in unrelated datasets from independent cohort of CRCs strongly suggest that Ras pathway signature may be a relevant expression signature predictive of CRC response to cetuximab. Our data seem to suggest that an mRNa expressing signature may also be developed as a predictive biomarker for drug response, similarly to genetic mutations.

Cite

CITATION STYLE

APA

Guo, S., Chen, D., Huang, X., Cai, J., Wery, J.-P., & Li, Q.-X. (2016). Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. Oncotarget, 7(31). https://doi.org/10.18632/oncotarget.10499

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free